- Adjusted cash costs ~$3.8B in 2026 (excl. $0.9B litigation charge).
Moderna cut costs faster than expected but will reinvest savings into oncology, especially the intismeran cancer vaccine. Cash costs will stay elevated through 2030, making successful drug launches critical for profitability. Shares fell 7% on Thursday.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.